High prevalence of serum metabolic alterations in primary Sjögren's syndrome: Influence on clinical and immunological expression

Journal of Rheumatology

Volumn 34, Issue 4, 2007, Pages 754-761

  Ramos Casals, Manuel ^a,c   Brito Zerón, Pilar ^a   Sisó, Antoni ^b   Vargas, Alfonso ^a   Ros, Emili ^a   Bove, Albert ^a   Belenguer, Rafael ^a   Plaza, Joan ^a   Benavent, Jaume ^c   Font, Josep ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Centre d'Assistència Primària ABS Les Corts   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Diabetes mellitus; Hypercholesterolemia; Hypertriglyceridemia; Serum metabolic alterations; Sj gren's syndrome

Indexed keywords

CHOLESTEROL; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CORTICOSTEROID; LA ANTIBODY; RO ANTIBODY; TRIACYLGLYCEROL; URIC ACID;

ADULT; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DISEASE MARKER; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; KIDNEY DYSPLASIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; PREVALENCE; PRIORITY JOURNAL; SJOEGREN SYNDROME; VASCULITIS;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIBODIES, ANTINUCLEAR; CASE-CONTROL STUDIES; DIABETES COMPLICATIONS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; MALE; MIDDLE AGED; SJOGREN'S SYNDROME;

EID: 34247384024     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Fox RI. Sjogren's syndrome. Lancet 2005;366:321-31.
2. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med 2004;164:1275-84.
3. Ramos-Casals M, Tzioufas AG, Font J. Primary Sjogren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 2005;64:347-54.
4. Kaltreider HB, Talal N. Bilateral parotid gland enlargement and hyperlipoproteinemia. JAMA 1969;210:2067-70.
5. Goldman JA, Julian EH. Pseudo-Sjogren syndrome with hyperlipoproteinemia. JAMA 1977;237:1582-4.
6. Robinson CP, Yamachika S, Alford CE, et al. Elevated levels of cysteine protease activity in saliva and salivary glands of the nonobese diabetic (NOD) mouse model for Sjogren syndrome. Proc Natl Acad Sci USA 1997;94:5767-71.
7. Ramos-Remus C, Suarez-Almazor M, Russell AS. Low tear production in patients with diabetes mellitus is not due to Sjogren's syndrome. Clin Exp Rheumatol 1994;12:375-80.
8. Binder A, Maddison PJ, Skinner P, Kurtz A, Isenberg DA. Sjogren's syndrome: association with type-1 diabetes mellitus. Br J Rheumatol 1989;28:518-20.
9. Lodde BM, Sankar V, Kok MR, Leakan RA, Tak PP, Pillemer SR. Serum lipid levels in Sjogren's syndrome. Rheumatology Oxford 2006;45:481-4. Epub 2005 Nov 22.
10. Vaudo G, Bocci EB, Shoenfeld Y, et al. Precocious intima-media thickening in patients with primary Sjogren's syndrome. Arthritis Rheum 2005;52:3890-7.
11. Garcia-Carrasco M, Ramos-Casals M, Rosas J, et al. Primary Sjogren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore) 2002;81:270-80.
12. Ramos-Casals M, Font J, Garcia-Carrasco M, et al. Primary Sjogren syndrome: hematologic patterns of disease expression. Medicine (Baltimore) 2002;81:281-92.
13. Vitali C, Bombardieri S, Moutsopoulos HM, et al. Preliminary criteria for the classification of Sjogren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993;36:340-7.
14. Ramos-Casals M, Anaya JM, Garcia-Carrasco M, et al. Cutaneous vasculitis in primary Sjögren syndrome. Classification and clinical significance of 52 patients. Medicine (Baltimore) 2004;83:96-106.
15. Trejo O, Ramos-Casals M, Garcia-Carrasco M, et al. Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore) 2001;80:252-62.
16. Slomiany BL, Kosmala M, Nadziejko C, et al. Lipid composition and viscosity of parotid saliva in Sjogren syndrome in man. Arch Oral Biol 1986;31:699-702.
17. Swanson CA, Levy JA, Morrow WJ. Effect of low dietary lipid on the development of Sjogren's syndrome and haematological abnormalities in (NZB x NZW)F1 mice. Ann Rheum Dis 1989;48:765-70.
18. Izumi M, Hida A, Takagi Y, Kawabe Y, Eguchi K, Nakamura T. MR imaging of the salivary glands in sicca syndrome: comparison of lipid profiles and imaging in patients with hyperlipidemia and patients with Sjogren's syndrome. AJR Am J Roentgenol 2000;175:829-34.
19. Jain S. Dry eyes in diabetes. Diabetes Care 1998;21:1375.
20. Feng L, Matsumoto C, Schwartz A, Schmidt AM, Stern DM, Pile-Spellman J. Chronic vascular inflammation in patients with type 2 diabetes: endothelial biopsy and RT-PCR analysis. Diabetes Care 2005;28:379-84.
21. Said G, Goulon-Goeau C, Lacroix C, Moulonguet A. Nerve biopsy findings in different patterns of proximal diabetic neuropathy. Ann Neurol 1994;35:559-69.
22. Antonelli A, Ferri C, Fallahi P, et al. Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients. Rheumatology Oxford 2004;43:238-40.
23. Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study. Arthritis Rheum 2004;50:1262-9.
24. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LTH. Lymphoma and other malignancies in primary Sjögren's syndrome. A cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006;65:796-803. Epub 2005 Nov 10.
25. Davidson MH. Management of dyslipidemia in patients with complicated metabolic syndrome. Am J Cardiol 2005;96:22E-25E.
26. Gurevich VS, Shovman O, Slutzky L, Meroni PL, Shoenfeld Y. Statins and autoimmune diseases. Autoimmun Rev 2005;4:123-9.
27. McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015-21.
28. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005;35:8-17.
29. Bruce IN. Atherogenesis and autoimmune disease: the model of lupus. Lupus 2005;14:687-90.
30. Sada KE, Yamasaki Y, Maruyama M, et al. Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol 2006;33:1545-52.
31. El Magadmi M, Ahmad Y, Turkie W, et al. Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol 2006;33:50-6.
32. Dessein PH, Joffe BI, Stanwix AE. Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. J Rheumatol 2003;30:1403-5.